Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) may be curative for colorectal cancer patients with peritoneal metastases (PMs) but it has a high rate of morbidity. Accurate preoperative patient selection is therefore imperative, but is constrained by the limitations of current imaging techniques. In this pilot study, we explored the feasibility of circulating tumor (ct) DNA analysis to select patients for CRS-HIPEC. Thirty patients eligible for CRS-HIPEC provided blood samples preoperatively and during follow-up if the procedure was completed. Targeted Next-Generation Sequencing (NGS) of DNA from PMs was used to identify bespoke mutations that were subsequently tested in corresponding plasma cell-free (cf) DNA samples using droplet digital (dd) PCR. CtDNA was detected preoperatively in cfDNA samples from 33% of patients and was associated with a reduced disease-free survival (DFS) after CRS-HIPEC (median 6.0 months vs median not reached, p = 0.016). This association could indicate the presence of undiagnosed systemic metastases or an increased metastatic potential of the tumors. We demonstrate the feasibility of ctDNA to serve as a preoperative marker of recurrence in patients with PMs of colorectal cancer using a highly sensitive technique. A more appropriate treatment for patients with preoperative ctDNA detection may be systemic chemotherapy in addition to, or instead of, CRS-HIPEC.

[1]  D. Moro,et al.  Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Sleijfer,et al.  RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer , 2019, Molecular oncology.

[3]  G. Kazemier,et al.  Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review , 2019, JNCI cancer spectrum.

[4]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[5]  A. Zwinderman,et al.  Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6) , 2019, BMC Cancer.

[6]  E. Oki,et al.  A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer , 2019, British Journal of Cancer.

[7]  M. Pocard,et al.  A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7. , 2019, European Journal of Surgical Oncology.

[8]  S. Lippman,et al.  Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival , 2019, JCO precision oncology.

[9]  F. De Keyzer,et al.  Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases , 2019, Cancer Imaging.

[10]  U. Sarpel,et al.  Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience , 2018, Annals of Surgical Oncology.

[11]  R. Beets-Tan,et al.  Diffusion‐weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery , 2018, The British journal of surgery.

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  K. Spindler,et al.  Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing , 2018, Translational oncology.

[14]  R. Kurzrock,et al.  Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival , 2018, Annals of Surgical Oncology.

[15]  M. Pocard,et al.  A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.

[16]  G. Kazemier,et al.  Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC , 2018, Annals of Surgical Oncology.

[17]  D. Elias,et al.  Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG‐RENAPE) , 2018, The British journal of surgery.

[18]  A. Aalbers,et al.  Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2018, Annals of Surgical Oncology.

[19]  K. Kinzler,et al.  Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study , 2018, Gut.

[20]  M. O'Leary,et al.  Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy , 2017, JAMA surgery.

[21]  H. Lang,et al.  Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection , 2017, Scientific Reports.

[22]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[24]  Rebecca M. Dodson,et al.  Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy , 2016, Annals of Surgical Oncology.

[25]  Bauke Ylstra,et al.  Sequencing Structural Variants in Cancer for Precision Therapeutics. , 2016, Trends in genetics : TIG.

[26]  J. Esquivel Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. , 2016, Journal of gastrointestinal oncology.

[27]  S. Nishizuka,et al.  Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel , 2016, PloS one.

[28]  H. Nielsen,et al.  Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.

[29]  A. Mirnezami,et al.  Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone , 2014, British Journal of Cancer.

[30]  P. Snijders,et al.  Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology , 2014, Cellular Oncology.

[31]  M. Wiezer,et al.  Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer , 2014, Journal of surgical oncology.

[32]  I. Nagtegaal,et al.  Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[34]  K. Havenga,et al.  Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol , 2013, Annals of Surgical Oncology.

[35]  H. Bonjer,et al.  Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. , 2013, Cancer treatment reviews.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[37]  N. Gusani,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis , 2010, Cancer.

[38]  C. Meijer,et al.  A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[39]  S. Bruin,et al.  8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2008, Annals of Surgical Oncology.

[40]  W. Oyen,et al.  Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies , 2006, Annals of surgery.

[41]  F. Zoetmulder,et al.  Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[42]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Jayne,et al.  Peritoneal carcinomatosis from colorectal cancer , 2002, The British journal of surgery.

[44]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[45]  P. Sugarbaker Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. , 1998, Seminars in surgical oncology.

[46]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[47]  B. Glimelius,et al.  Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. , 2016, European journal of cancer.

[48]  M. Ducreux,et al.  Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. , 2014, European journal of cancer.

[49]  B. Ylstra,et al.  High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed, paraffin-embedded tissues. , 2012, Methods in molecular biology.

[50]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Bracke,et al.  Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. , 2009, The Lancet. Oncology.

[52]  M. P. Tristan D. Yan BSc,et al.  Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis , 2008, Annals of Surgical Oncology.

[53]  A. Witkamp,et al.  Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin , 2004, Annals of Surgical Oncology.